Frontiers in Clinical Drug Research : Anti - infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees. The 7 reviews included in this volume are: - Monoclonal antibodies as therapeutic agents for inflammatory diseases - Pharmacotherapy of emerging antiviral agents - Antiviral activity of vitamin D and COVID-19: current understanding - Anti-infectives to combat leishmaniasis - Anthelmintic drug discovery: current situation and future perspectives - Therapeutic targets for emerging Zika virus infection and vaccines in clinical trials - Agro-industrial waste: new source of raw material for the control of American foulbrood in honey bees

Anti-infective agents are a distinct class of pharmacologically important molecules that have served mankind in different capacities to combat life-threatening pathological conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial, and urinary anti-infective agents. However, evolutionary changes, adaptations, and the development of new strains of pathogenic microorganisms have reduced the therapeutic efficacy of existing drugs, thus, limiting their clinical utility over the years. Frontiers in Anti-Infective Agents Volume 6 is a collection of notable research efforts, successful anti-infective drug development programs, and a comprehensive overview of successful and unsuccessful clinical trials conducted in this domain. This volume continues from the last one with interesting reviews on 1) “Reverse Vaccinology” for vaccination design using computational data to identify vaccine targets, 2) leptospirosis, 3) phage therapy for bacterial infections, 4) quorum sensing inhibitors from natural products, and 5) nitrogen and oxygen-based heterocyclic compounds that can act as anti-infective agents. The volume, therefore, covers a range of frontier topics on anti-infective research and development. This compilation is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

In this book volume-2 proposal has been classified into Part IV: Models for SARS-CoV-2 and Part V: Treatment Strategies for SARS-CoV-2. With the emergence of new coronavirus variants, epidemiology, different host tropism permits a thorough analysis of their evolution and acquired adaptability to their host which need different animal models and treatment approaches. No studies are complete without animal models closely related to human physiology to replicate the disease and observe the pathology conditions as in human cases. Such animal models play a vital role in virus pathogenesis and prepare a therapeutic immune response. Here describe bio-engineered transgenic mouse model inserting with specific genes, or CRISPR-Case9 gene-editing tool has been used previously for SARS-CoV and MERS-CoV. The chapter will deal with culture techniques or cell lines for COVID-19—also histopathology of COVID-19, essential proteins that up or down-regulate SARS-CoV-2. The last chapter of this part will describe other diseases having similar signs and symptoms and their differentiation. There is no specific treatment available to date, just symptomatic therapy. However, scientists will elucidate effective antiviral drugs in clinical trials, phytochemicals, photomedicine such as ultraviolet A & B, homemade remedies, blood plasma transfusion, stem cell therapy, and computational approaches in vivo and in vitro trials. This book will appear as a baseline for academicians, scientists, and health professionals as still, research is going to overcome this outbreak of COVID-19, the novelty of best animal models, and find an effective treatment. However, just a single book proposal like this wouldn't have flourished without enthusiasm and determined publishers' and investigators' strength to take time from their busy schedule and subsidize on time. We thank the whole investigators who contributed, directly and indirectly, to bring it to reality.

Herbal Medicine: Back to the Future compiles expert reviews on the application of herbal medicines (including Ayurveda, Chinese traditional medicines and alternative therapies) to treat different ailments. The book series demonstrates the use of sophisticated methods to understand traditional medicine, while providing readers a glimpse into the future of herbal medicine.

Volume 5 continues the theme of the previous volume by featuring reviews of plant based therapies useful for treating different infectious diseases. Topics in this volume are of general interest to computational chemistry researchers, physicians and a broad range of allied healthcare practitioners. Other highlights of this volume include contributions about COVID-19, and traditional medicine in Algeria and China. The topics included in this volume are:

- Improving curcumin and eugenol through computational chemistry and nanotechnology

- Herbal remedies for respiratory tract infections

- COVID-19 pandemic: a comprehensive overview of epidemiological, pathogenesis, diagnostic aspects and therapeutic interventions to tackle current outbreak

- Application of mid-infrared spectroscopy on therapeutic effects of herbal medicine in infectious diseases

- Traditional herbal uses from Algerian pharmacopoeia against infectious diseases

- Traditional Chinese medicine for treating infectious diseases: history, progress, and perspectives

This volume is essential reading for all researchers in the field of natural product chemistry and pharmacology. Medical professionals involved in internal medicine who seek to improve their knowledge about herbal medicine and alternative therapies for tropical and other infectious diseases will also benefit from the contents of the volume.

COVID-19: Epidemiology, Biochemistry, and Diagnostics explains COVID-19 from multidisciplinary angles such as the evolution of SARS-COV, genetic techniques to study the virus, and diagnostic methodologies widely used in the global COVID-19 pandemic. The chapters in this book provide the reader with up-to-date literature about research on SARS-CoV-2 through three parts: I) Evolution and Entry of SARS-CoV-2 into the host II) Genetic Alteration and Structural Determination of SARS-CoV-2 Proteins III) Quantitative Analysis of SARS-CoV-2 for research and medical diagnosis Key Features: - 15 chapters on SAR-CoV-2 in a multidisciplinary context - Provides a comprehensive overview of SARS-CoV-2 evolution and genetics - Provides biochemical information about SARS-CoV-2 proteins and receptor targets (both structural and non-structural proteins) - Includes an overview of several methods of detecting SARS-CoV-2 virus particles (ELISA, PCR, Neutralizing Antibodies - Covers some critical diagnostic modalities for COVID-19 diagnosis - Provides bibliographic references for further reading Readers will understand the significance of phylogenetic analysis of coronaviruses, along with the pathogenesis of COVID-19 and related diseases such as SARS and MERS. Applications of biochemical technologies such as RT-PCR and CRISPR are also demonstrated in the text. This book is a comprehensive introduction to COVID-19 research for medical researchers, microbiologists and virologists. Students in academic programs in life sciences and medicine will also benefit from the information provided in the book.

Anti-infective agents are a distinct class of pharmacologically important molecules that has served mankind in different capacities to combat life-threating pathologic conditions. They include antibacterial, antifungal, antiviral, antituberculosis, antimalarial and urinary anti-infective agents. However, evolutionary changes, adaptations and development of pathogenic microorganisms strains the therapeutic efficacy of these drugs thus limiting their clinical utility over the years. Frontiers in Anti-Infective Agents Volume 5 is a collection of notable research efforts, successful anti-infective drug development programmes and a comprehensive overview of the successes and failures of recent clinical trials in this domain. The volume covers interesting topics: 1) the treatment of acute wounds with the vikut® formula, 2) anti-infective treatment of ocular diseases and 3) sars-cov vaccine development and antimicrobial therapy for SARS symptoms. A chapter summarizing recent anti-infective approaches rounds up the contents of this volume. This volume is a timely reference for postgraduate scholars and researchers seeking updates in specific areas of anti-infective drug development. Allied healthcare professionals (clinical and public healthcare professionals) can also benefit from the information presented within.

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series should prove to be of interest to all pharmaceutical scientists involved in research in anti-cancer drug design and discovery. The book series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. This volume of the series focuses on reviews of treatments derived from natural sources (cannabinoid-based medicines and turmeric), immunotherapy, biomarkers for glioblastoma and some new drug targets for anti-cancer treatment. The reviews included in this volume are: - Cannabinoid-Based Anticancer Strategies: - The Beneficial Effects of Turmeric and Its Active Constituent in Cancer Treatment - Immunotherapy Approaches Focusing on Cancer Stem Cells - Immunotherapy for the Treatment of Hepatocellular Carcinoma - Role of Biomarkers in Developing Therapies for Glioblastoma Multiforme - Poly (ADP-ribose) Polymerases as New Drug Targets in Cancer Treatment

Scientific literature on SARS-COV-2 viruses and its variants (especially variants of concern such as the ‘Delta variant’) and important cellular targets is crucial to help researchers, epidemiologists, virologists and clinicians around the globe to develop a new generation of safer and more effective vaccines, and other treatments to address COVID-19 disease. The accompanying damage to the many organs and tissues of SARS-Co-2-infected people also needs to be understood and researchers are using data to devise meaningful protocols for treating these symptoms. This second volume of Coronaviruses brings together more useful information about the prevention, vaccination, and chemotherapies for the potential treatment of coronavirus infections. The volume includes eight chapters: (1) Broad spectrum antivirals to combat COVID-19 The reality and challenges, (2) COVID-19: Preventive and protective control management strategies, (3) Plant-derived extracts and bioactive compounds against coronavirus progression: preventive effects, mechanistic aspects, and structures, (4) Gastroenteritis: symptoms and epidemiology of SARS-CoV-2, (5) The chronicles of coronavirus: A Chinese king who conquered the entire world, (6) Traditional medicine as a natural remedy in ARDS & COVID-19, (7) Molecular pathogenesis of human coronaviruses of the 21st century, (8) COVID-19, mental health and neuropathophysiology of pain related to temporomandibular disorder. The volume serves as a novel compilation of key data on SARS-CoV-2 and COVID-19 and represents a resource of the utmost value for all scholars studying SARS-CoV infections. It should also be of great interest to clinicians who may be facing an overwhelming number of individuals affected with COVID-19, with over 267 million global cases documented as of the first week of December 2021).

Influenza is one of the most ancient and intriguing diseases that has been accompanying our civilization for millennia. While mankind has successfully defeated many dangerous influenza infections in the last couple of centuries, influenza control remains a serious problem for public health. A number of influenza vaccines and antiviral compounds have been licensed in recent times. However, the influenza virus is still ahead of us, as it continues to persistently infect humans to this day. Influenza: A Century of Research shows how influenza virology has developed historically and the tremendous knowledge that has been uncovered in the study of influenza. In this monograph, the authors present a historical perspective on influenza, chronologically, with an emphasis on its virology. Chapters cover information about the isolation of the first influenza viruses, substrates, and models for studying influenza, structure, and life cycle of the influenza virus, mechanisms of attenuation and virulence. Chapters progress into the multidisciplinary aspects of influenza research such as influenza virus ecology and the evolutionary origin of epidemic and pandemic influenza viruses. A significant part of the book also covers the description of the prevention and treatment of influenza and reasons that have contributed to insufficient control for influenza. The questions of how the COVID-19 pandemic affects the circulation of seasonal respiratory viruses, and if we can eliminate this virus are also addressed. Influenza: A Century of Research is an informative source of information for a broad range of readers, academic or otherwise, who are interested in knowing more about the disease.

Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. </p> The seventh volume of this series features these interesting reviews: </p> - Nucleic acid and peptide aptamers as potential antiviral drugs </p> - Host-directed, antibiotic-adjuvant combination, and antibiotic-antibiotic combinations for treating multidrug-resistant (mdr) gram-negative pathogens </p> - Bioactive substances as anti-infective strategies against clostridioides difficile </p> - Anti-toxoplasma drug discovery and natural products: a brief overview </p> - Development of antimalarial and antileishmanial drugs from amazonian biodiversity